Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tango Therapeutics, Inc. (TNGX : NSDQ)

• Company Description    Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass. Number of Employees: 155

• Price / Volume Information    Yesterday's Closing Price: $8.86 Daily Weekly Monthly 20 Day Moving Average: 2,355,281 shares Shares Outstanding: 134.68 (millions) Market Capitalization: $1,193.24 (millions) Beta: 1.75 52 Week High: $11.20 52 Week Low: $1.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.51% -10.35% 12 Week 21.04% 19.09% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 BROOKLINE AVE. SUITE 901 - BOSTON,MA 02215 USA ph: 857-320-4900 fax: - ir@tangotx.com http://www.tangotx.com

• General Corporate Information    Officers Barbara Weber - Chief Executive Officer; President and Director Alexis Borisy - Chairman Daniella Beckman - Chief Financial Officer Lesley Ann Calhoun - Director Kanishka Pothula - Director Peer Information Tango Therapeutics, Inc. (CORR.) Tango Therapeutics, Inc. (RSPI) Tango Therapeutics, Inc. (CGXP) Tango Therapeutics, Inc. (BGEN) Tango Therapeutics, Inc. (GTBP) Tango Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87583X109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 134.68 Most Recent Split Date: (:1) Beta: 1.75 Market Capitalization: $1,193.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.45 Price/Cash Flow: - Price / Sales: 17.94 EPS Growth vs. Year Ago Period: 148.15% vs. Previous Quarter: 137.14% Sales Growth vs. Year Ago Period: 363.61% vs. Previous Quarter: 1,591.64% ROE 12/31/25 - - 09/30/25 - -60.80 06/30/25 - -79.72 ROA 12/31/25 - - 09/30/25 - -38.70 06/30/25 - -49.30 Current Ratio 12/31/25 - - 09/30/25 - 8.88 06/30/25 - 4.75 Quick Ratio 12/31/25 - - 09/30/25 - 8.88 06/30/25 - 4.75 Operating Margin 12/31/25 - - 09/30/25 - -151.15 06/30/25 - -599.11 Net Margin 12/31/25 - - 09/30/25 - -151.15 06/30/25 - -599.11 Pre-Tax Margin 12/31/25 - - 09/30/25 - -150.99 06/30/25 - -598.40 Book Value 12/31/25 - - 09/30/25 - 1.19 06/30/25 - 1.21 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©